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Influenza virus sialidase has an essential role in the virus’ life cycle. Two distinct groups 
of influenza A virus sialidases have been established, that differ in the flexibility of the 
‘150-loop’, providing a more open active site in the apo form of the group-1 compared to group-2 
enzymes. In this study we show, through a multidisciplinary approach, that novel sialic acid-
based derivatives can exploit this structural difference and selectively inhibit the activity of 
group-1 sialidases. We also demonstrate that group-1 sialidases from drug-resistant mutant 
influenza viruses are sensitive to these designed compounds. moreover, we have determined, 
by protein X-ray crystallography, that these inhibitors lock open the group-1 sialidase flexible 
150-loop, in agreement with our molecular modelling prediction. This is the first direct proof 
that compounds may be developed to selectively target the pandemic A/H1n1, avian A/H5n1 
and other group-1 sialidase-containing viruses, based on an open 150-loop conformation of 
the enzyme.
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Influenza remains a serious health concern to humanity, with high morbidity and mortality rates1,2 and the recent influenza A/H1N1 pandemic underscores the potential threat of this highly adaptive 
virus3. The sialidase (neuraminidase) of influenza virus has a major 
role in the virus’ life cycle by facilitating release of virus progeny 
from the infected cell4. Two phylogenetically distinct groups5 of 
influenza A virus sialidases, group-1 (N1, 4, 5 and 8) and group-2 
(N2, 3, 6, 7 and 9), have been established. The anti-influenza drugs6 
(Fig. 1) Relenza (zanamivir, 1) and Tamiflu (oseltamivir, 2), through 
its active form oseltamivir carboxylate (OC, 3), efficiently block the 
activity of both influenza A virus group-1 and group-2 sialidases, 
resulting in the virus progeny remaining clumped at the infected 
cell’s surface. Noteworthy is that the discovery of these inhibitors 
was based exclusively on group-2 sialidase structures6.
The recently solved5 structures of group-1 sialidases showed an 
unexpected structural difference between group-1 and group-2 
sialidases, with the group-1 sialidases having a loop, the so-called 
‘150-loop’, that is flexible compared with the identical loop of the 
group-2 sialidases. This protein loop can provide either a more open 
(group-1) or closed (group-2) active site architecture in the apo form 
of the enzyme. Furthermore, the 150-loop, in initially complexed 
structures of 3–group-1 sialidase5, has been observed in the more 
open orientation and eventually closes and tightly coordinates 3. In 
contrast, a very recent structural investigation on the 2009 pandemic 
H1N1 sialidase concluded that this group-1 enzyme seems to lack a 
150-cavity7. It has been proposed that the more open enzyme archi-
tecture and consequently larger active site cavity in the apo structures 
of the group-1 sialidases could provide new opportunities for inhibi-
tor design5,6,8,9. In the context of the recent pandemic swine origin 
A/H1N1 and the pandemic 1918 A/H1N1 influenza viruses, as well 
as the continuing threat of avian A/H5N1, such inhibitors could 
lead to new anti-influenza drugs that would add to the very limited 
number of treatment options available.
The potent influenza virus sialidase inhibitors 1 and 3 show 
essentially comparable inhibition of influenza A virus group-1 
and 2 sialidases8. This is not surprising as these inhibitors do not 
have the capacity to maintain the 150-loop of group-1 sialidases 
in an open orientation. An important question remains to be 
answered—could the 150-loop of influenza A virus group-1 siali-
dases be locked open to provide new opportunities in influenza 
virus sialidase inhibitor design? Moreover, could such ‘designer’ 
compounds that lock open this loop also selectively inhibit group-
1 sialidases, including the pandemic swine origin H1N1 sialidase. 
Interestingly, C-4-modified zanamivir (1) derivatives have been 
recently reported that are believed to take advantage of this open 
150-loop feature, although neither selectivity nor structural data 
have been presented in support of this conclusion10. More recently 
OC (3) analogues have been reported11 that efficiently inhibit and 
are selective for a group-1 influenza virus sialidase. These com-
pounds are thought to access the 150-cavity, and preliminary 
nuclear magnetic resonance (NMR) spectroscopic evidence for 
this conclusion is reported.
To probe and attempt to lock open the 150-loop of influenza 
virus group-1 sialidases, we have undertaken a multidisciplinary 
study that used molecular modelling, chemical synthesis, enzyme 
and cell-based assays and protein X-ray crystallography. We have 
successfully designed and synthesized novel C-3-substituted sialic 
acid-based derivatives that efficiently and selectively inhibit group-
1 sialidase activity by locking open the flexible 150-loop. These 
derivatives contain the zanamivir (1) core structure, although they 
lack the C-4 guanidino moiety, and incorporate a hydrophobic 
entity at the C-3 position. Moreover, we have demonstrated that 
these inhibitors are also effective against influenza virus clinical 
isolates containing mutations in the sialidase glycoprotein that 
convey resistance to oseltamivir (2) and reduced sensitivity to 
zanamivir (1).
Results
Molecular modelling study of a group-1 sialidase. Our modelling 
study commenced with the superimposition of two group-1 
sialidase N8 structures, apo N8 (2ht5) and the N8–4 complex (2htr), 
which contain an open and closed 150-loop, respectively. This 
provided an opportunity to view the well-known sialidase inhibitor 
5-acetamido-2,6-anhydro-3,5-dideoxy-d-glycero-d-galacto-non-
2-enonic acid (Neu5Ac2en, 4, Fig. 1) modelled in the context of 
a sialidase active site with an open 150-loop conformation. We 
concluded from this inspection that carbon-3 (C-3) of Neu5Ac2en 
(4) is oriented towards the 150-cavity in the more open form of the 
enzyme. As a consequence, we then used 4 as a template (Methods) 
to design probes of this cavity. This design study suggested that 4 
modified at C-3 should be able to bind to the active site of apo-N8 
with minimal distortion of the normal binding mode. Moreover, 
our modelling indicated that hydrophobic functionalities, such as 
an allyl or arylallyl group, introduced at C-3 on template 4, should 
be accommodated in the 150-cavity. Finally, our modelling study 
also suggested that such functionalities would lock open the 150-
loop and, as a direct outcome, should be selective for the influenza A 
virus group-1 sialidases. Interestingly, the C-3 position on 4, to the 
best of our knowledge, has never been functionalized.
Synthesis of novel sialic acid derivatives. To explore novel func-
tionalization of the C-3 position of 4, we chose chemistries that 
would introduce a functional group that could be readily elabo-
rated. We believed that introduction of an allyl group would provide 
significant opportunity to elaborate the new functionality through 
olefin cross-metathesis reactions12. Our strategy to access this novel 
class of chemical probe utilized the per-O-acetylated, methyl ester 
derivative of 4 (Fig. 2, Supplementary Methods). From this deriva-
tive, we were able to readily prepare the target compounds (Fig. 1), 
3-allyl-Neu5Ac2en (5) and 3-(p-tolyl)allyl-Neu5Ac2en (6).
Biological evaluation of sialic acid derivatives. To assess the abil-
ity of these compounds to selectively block the enzyme activity of 
group-1 influenza A virus sialidases, 5 and 6 have been evaluated in 
OHO2C
NH
NHAc
OH
OH
OH
1
H
NH2
HN
RO2C
NH2
NHAc
H
2  R = Et
3  R = H
OHO2C
OH
NHAc
OH
OH
OH
4
H
OHO2C
OH
NHAc
OH
OH
OH
H
R
5  R = H
6  R = CH3
C-3
O
Figure 1 | Chemical structures of anti-influenza viral drugs and influenza 
virus sialidase inhibitors. Zanamivir (1), oseltamivir (2), oseltamivir 
carboxylate (3), neu5Ac2en (4), 3-allyl-neu5Ac2en (5) and  
3-(p-tolyl)allyl-neu5Ac2en (6).
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an in vitro fluorometric assay13 against both wild-type and mutant 
group-1 (N1) and a wild-type group-2 (N2) viral sialidase (Meth-
ods). As anticipated, both probes 5 and 6 indeed showed selectiv-
ity for the group-1 (N1) sialidases compared with the group-2 (N2) 
sialidase (Table 1), with a micromolar level of inhibition deter-
mined for 6 against the N1 sialidases. This is in distinct contrast 
to the parent inhibitor Neu5Ac2en (4), also a micromolar inhibi-
tor, that shows comparable inhibition of both group-1 and group-2 
sialidases. These data support the notion that 5 and 6 access a novel 
subsite within the influenza virus group-1 sialidase active site, such 
as that observed in the open 150-loop conformation5. Moreover, 
both of the sialic acid-based probes displayed activity against N1 
sialidases associated with clinically relevant viruses8 with mutations 
that affect sensitivity to both 1 and 2 (Table 1). Finally, the selectiv-
ity for inhibition of N1 over N2 sialidase activity, shown by 5 and 6, 
was confirmed by plaque reduction assay studies (Supplementary 
Fig. S1) and 50% effective concentration (EC50) determinations 
(Supplementary Table S1).
Structures of group-1 sialidase N8–5 and 6 complexes. Influ-
enza virus sialidase N8 [A/duck/Ukraine/1/63 (H3N8)] was used 
as a convenient and representative group-1 sialidase for structural 
studies. Both probes 5 and 6 were successfully complexed with 
N8 and structures readily determined. Both inhibitors 5 and 6 in 
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Figure 2 | Preparation of 3-allyl-Neu5Ac2en (5) and 3-(p-tolyl)allyl-Neu5Ac2en (6). Reagents and conditions: (a) nBs, Dmso/H2o (2.5:1),  − 30 °C,  
2 h (38% di-equatorial bromohydrin 8, 28% di-axial bromohydrin); (b) Bu3snAll, AIBn, dry toluene, n2, 100 °C, 8 h (57%); (c) Ac2o, dry pyridine,  
DmAP, n2, room temperature, 16 h (95%); (d) AcCl, dry meoH, dry DCm, 5 °C to room temperature, 48 h; (e) DBu, dry DCm, n2, room temperature,  
8 h (91% over steps d and e, based on recovered starting material); (f) Grubbs’ catalyst second generation, 4-methylstyrene, dry DCm, n2, 40 °C, 24 h  
(69%; 77% based on recovered starting material). (g) 1 m aq. naoH, meoH, 5 °C to room temperature, 12–16 h (5 and 6, 60%, based on recovered 
starting material, and 94%, respectively).
Table 1 | Selective inhibition of influenza A group-1 sialidase by locking open the 150-loop.
Sialidase type Ki (mM)*
 5  6  4  1
n1 (A/HongKong/156/97 (H5n1)) 222  ±  17 7.3 ± 0.8 0.97 ± 0.15 0.17 ± 0.08×10 − 3
n1 (A/Paris/2590/2009 (H1n1 pandemic)) 153  ±  18 1.7 ± 0.2 0.67 ± 0.08 0.13 ± 0.01×10 − 3
n2 (A/Paris/908/97 (H3n2)) 3629  ±  2130 219 ± 30 1.24 ± 0.23 0.56 ± 0.16×10 − 3
n1 (A/HongKong/156/97 (H5n1) H274Y) 459  ±  92 11 ± 0.9 1.43 ± 0.17 0.38 ± 0.14×10 − 3
n1 (A/Paris/2590/2009 (H1n1 pandemic) H274Y) 232  ±  15 2.9 ± 0.1 0.91 ± 0.05 0.23 ± 0.04×10 − 3
n1 (A/HongKong/156/97 (H5n1) n294s) 980  ±  50 25 ± 3.1 3.90 ± 0.5 0.71 ± 0.04×10 − 3
n1 (A/HongKong/156/97 (H5n1) Q136K) 16.8  ±  2.5 2.6 ± 0.4 1.37 ± 0.15 13.6 ± 1.3×10 − 3
Inhibition of wild-type n1, H274Y, n294s and Q136 K mutant n1 sialidases, and an n2 sialidase by 5 and 6 compared with parent template 4 and zanamivir (1).
*Results are given as means  ±  s.d. (see methods—Inhibition Assays for details).
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complex with N8 (N8–5, Fig. 3, Supplementary Fig. S2, Supplemen-
tary Movie 1; N8–6, Fig. 4, Supplementary Fig. S3, Supplementary 
Movie 2) clearly demonstrated that the C-3 functionalities occupied 
the cavity formed by the open 150-loop.
Discussion
On the basis of our structure-assisted studies, we identified 3-allyl-
Neu5Ac2en (5) as an important versatile chemical intermediate for 
influenza virus sialidase inhibitor development. Our synthetic strat-
egy to access 5 required the corresponding 3-substituted N-acetyl-
neuraminic acid derivative, fully protected 3-allyl-Neu5Ac (10) 
(Fig. 2). This derivative was synthesized from fully protected Neu-
5Ac2en (7) through bromohydroxylation14, and subsequent reaction 
of the di-equatorial bromohydrin 8 with allyltributyltin15. Reacting 
8 with allyltributyltin in toluene at elevated temperature in the pres-
ence of the free radical initiator AIBN resulted in an improved yield 
of 9 (57%) compared with that reported15 for the ultraviolet light-
catalysed reaction (34%). Acetylation of 9 provided intermediate 10 
in good yield (95%). Chlorination of 10 at C-2 provided 11, with sub-
sequent β-elimination of HCl in the presence of 1,8-diazabicyclo-
[5.4.0]undec-7-ene (DBU), resulting in the formation of the novel 
C-3-substituted 2,3-unsaturated derivative 12. The side chain at 
C-3 could be efficiently extended using an olefin cross-metathesis 
reaction12. Accordingly, reaction of allyl derivative 12 with 4-meth-
ylstyrene in the presence of Grubbs’ catalyst (second generation)16 
produced the 3-(p-tolyl)allyl derivative 13 in 69% isolated yield 
(corrected to 77% based on recovered 12). We observed that the 
cross-metathesis reaction was stereoselective and provided the ther-
modynamically more stable (E)-isomer. This was confirmed by a 
1H NMR coupling constant (J1,2) for the trans-olefinic hydrogens of 
15.9 Hz. Exposure of 12 and 13 to standard base-catalysed deprotec-
tion conditions gave the target 3-allyl-Neu5Ac2en (5) in a 51% yield 
(60% yield based on recovered 12), and 3-(p-tolyl)allyl-Neu5Ac2en 
(6) in a 94% yield, following isolation and purification.
Our initial biological evaluation of 5 and 6 against wild-type 
influenza virus sialidases confirmed that both compounds were 
selective inhibitors of group-1 sialidases (Table 1). Plaque reduction 
assay and EC50 determinations confirmed that 6 selectively inhib-
ited the growth of wild-type N1-containing viruses compared with 
a wild-type N2-containing virus (Supplementary Fig. S1 and Sup-
plementary Table S1). Importantly, our data revealed that the 2009 
pandemic H1N1 virus and N1 sialidase are as sensitive to these C-3 
functionalized sialic acid derivatives as the other evaluated group-
1 viruses and sialidases. This observation contrasts a very recent 
report7, in which the conclusion reached was that this particular 
group-1 sialidase lacks a 150-cavity. Therefore, we propose that the 
2009 pandemic H1N1 sialidase does have an accessible 150-cavity 
that is exposed to some extent upon the binding of an appropriate 
inhibitor such as 5 or 6.
Oseltamivir (2) resistance among influenza A/H1N1 viruses 
has rapidly emerged over the previous two influenza seasons17. The 
observation8,17 of significant resistance development to oseltamivir 
(2) and apparent reduced18 sensitivity to zanamivir (1) led us to 
investigate the affinity of these novel sialic acid derivatives for three 
influenza virus sialidases that contain well-characterized key muta-
tions. Each of these sialidases contained one of the following muta-
tions (N2 numbering), H274Y (H275Y in N1 numbering), N294S, or 
Q136K, which influence the efficacy of the sialidase-targeting drugs. 
Our data (Table 1) suggest that N1 with an H274Y mutation, which 
significantly reduces OC (3) sensitivity8,17, remains sensitive to 5 
and 6. The level of inhibition for these compounds follows the same 
apparent trend (approximately a factor of 2 poorer affinity compared 
with wild-type enzyme) that is observed for both zanamivir (1) and 
Neu5Ac2en (4). The N294S mutation reduces sensitivity to 5 and 
6 by approximately the same factor (~3.5) determined for 1 and 4. 
Strikingly, the Q136K mutation, that reduces sensitivity to zanamivir 
(1) and to a lesser extent 4, significantly increases sensitivity to the 
novel sialic acid derivatives 5 and 6. This improvement in sensitivity 
a b
Figure 3 | N8–5 complex. (a) superimposition of n8–inhibitor complexes of 3-allyl-neu5Ac2en (5, green) and neu5Ac2en (4, magenta; 2htr). (b) n8–5 
complex with open 150-loop (5 in CPK format). The n8–5 complex maintains the open conformation of the 150-loop seen in the apo structure5 (a, b).
a b c
Figure 4 | N8–6 complex. (a) superimposition of n8–inhibitor complexes of 3-(p-tolyl)allyl-neu5Ac2en (6, cyan) and neu5Ac2en (4, magenta; 2htr).  
(b) n8–6 complex with an open 150-loop (6 in CPK format). (c) n8–4 complex with a closed 150-loop5 (4 in CPK format). The n8–6 complex maintains 
an open conformation of the 150-loop seen in the apo structure5 (a,  b), in contrast to the complex with 4 where the 150-loop is closed (c).
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may be the result of an increase in hydrophobicity, contributed by 
the lysine side chain, of the active site region that consequently 
better accommodates the lipophilic moiety at C-3 of 5 and 6.
These data taken together suggest that a C-3-modified sialic 
acid derivative, such as 6, may provide a valuable lead compound 
for next generation anti-influenza drug discovery. Moreover, the 
introduction of the additional hydrophobic character may provide 
opportunity for these compounds, unlike zanamivir (1), to be devel-
oped as orally bioavailable drugs.
To provide direct proof of the binding mode of 5 and 6 with a 
group-1 sialidase, the compounds were soaked into preformed 
crystals of N8 sialidase [A/duck/Ukraine/1/63 (H3N8)], in which 
the 150-loop is in the open conformation5. The N8–5 (Fig. 3a and 
b, Supplementary Fig. S2 and Supplementary Movie 1) and N8–6 
(Fig. 4a and b, Supplementary Fig. S3, and Supplementary Movie 2) 
complexes obtained after a 60-min soak show that both 5 and 6 are 
positioned in the active site as anticipated. In both complexes, the 
dihydropyran ring, the C-6 glycerol side chain (showing a bidentate 
interaction between the C-8 and C-9 hydroxyl groups and Glu-276), 
and the C-4 hydroxyl and C-5 acetamido groups are oriented essen-
tially as seen with Neu5Ac2en (4) (PDB:2htr)5. The C-3 allyl and 
(p-tolyl)allyl group of 5 and 6, respectively, extend into the 150- 
cavity, as predicted, locking the 150-loop open. Under similar soaking 
conditions, the N8–4 complex (Fig. 4c) has the 150-loop in a closed 
conformation5. An interesting difference observed in the N8–5 com-
plex (Fig. 3), compared with the apo structure or the open 150-loop 
complex with 3 (ref. 5), is the position of Arg-118, one of the three 
arginine residues that normally complexes the Neu5Ac2en carboxy-
late group. In the N8–5 complex, Arg-118 is oriented away from 
the position seen in the other two open 150-loop structures and as 
a consequence no longer forms a hydrogen bond with the carboxy-
late group of 5 (Fig. 5). This observation suggests that there is more 
flexibility in this region of the active site than previously thought and 
may provide additional direction in future influenza virus sialidase 
inhibitor development. In a previous molecular modelling study19, 
the notion of flexibility in this region of the active site was predicted. 
In another study20, the triarginyl cluster interaction with the sialic 
acid carboxylate group has been calculated to contribute ~50% of the 
overall binding energy and so represents one of the strongest influ-
ences on substrate binding to the sialidase active site. The loss of inter-
action with Arg-118 could be expected to contribute to the in vitro 
sialidase inhibition observed for 5 in comparison with inhibitors that 
have interaction with all three residues of the triarginyl cluster.
Although movement of Arg-118 was observed in the N8–5 com-
plex (Figs 3 and 5), compared with the apo structure or the open 
150-loop complex with 3 (ref. 5), the N8–6 complex (Figs 4 and 5) 
clearly shows that 6 binds in a manner that does not induce any 
significant reorientation of active site amino-acid residues. The 150-
loop structure, the triarginyl cluster that forms a hydrogen bond 
with the carboxylate group of 6 and other key amino acids are all in 
a similar orientation5 to that seen in the apo open 150-loop struc-
ture (2ht5) (Fig. 5). Interestingly, the amino-acid residue Glu-119 in 
the apo form and in both the N8–5 and N8–6 complexes has a very 
similar orientation, and is quite distinct from the closed loop form, 
as observed in the N8–4 complex (Fig. 5). Clearly, a reorientation of 
this residue occurs as the active site closes around inhibitor 4. The 
fact that both the parent inhibitor 4 and 6 are micromolar inhibi-
tors suggests that the loss of interactions between the C-4 hydroxyl 
group of 4 and active site residue Glu-119 of the closed 150-loop 
form5 is almost completely compensated for by new hydrophobic 
interactions between the aromatic moiety at C-3 in 6 and the 150-
cavity (Fig. 6). Compound 6 provides a lead scaffold that, guided by 
structural analysis, can be further modified at the C-3 functional-
ity itself or the C-4 position, as was the case for zanamivir. As can 
be seen in Figure 6, the open cavity has significant positive charge 
character and provides scope for introduction of negatively charged 
substituents. Such modifications offer considerable opportunity for 
the development of potent influenza virus sialidase inhibitors.
In conclusion, we have demonstrated that it is possible, using 
appropriately substituted Neu5Ac2en derivatives, to lock open the 
flexible 150-loop of influenza A virus group-1 sialidases. Moreover, 
these derivatives demonstrate selectivity for an influenza A virus 
group-1 sialidase compared with a group-2 sialidase and the capac-
ity to inhibit oseltamivir-resistant influenza virus sialidases. Further 
studies using the C-3-substituted Neu5Ac2en template may help to 
determine whether group-2 sialidases also possess, as suggested by 
molecular dynamics simulations19,21, some plasticity or flexibility in 
this area of the protein. Finally, the most recent and the most dev-
astating pandemic influenza A viruses, swine origin H1N1 and the 
1918 H1N1 respectively, both contain a group-1 sialidase. This study 
may provide and inform new direction in the discovery of novel 
influenza virus sialidase inhibitors as next generation, first-line-of-
defence, anti-influenza drugs to specifically tackle such viruses.
Arg-118 Glu-119
Asp-151
150-loop
4.8A
3.1A
Figure 5 | Superimposition of N8 structures. superimposition of the open 
150-loop of n8–6 (cyan) and n8–5 (green), apo-n8 (pale orange; 2ht5) 
complexes, and the closed 150-loop of n8–4 (magenta; 2htr).
Figure 6 | Electrostatic potential map of the N8–6 complex. n8–6 complex 
showing electrostatic potential on the protein surface (red, negative; blue, 
positive; and white, neutral/hydrophobic). neu5Ac2en (4), in magenta, is 
superimposed on 6.
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Methods
Molecular modelling. Superimposition of the influenza A virus sialidase apo-N8 
structure (2ht5) and the N8–4 structure (2htr) using DeepView (Swiss-PDB-
Viewer)22 was visually inspected in Astex Viewer23. Several Neu5Ac2en (4) deriva-
tives substituted at the C-3 position, including 5 and 6, were then built in InsightII24 
and docked using AutoDock 3.0.5 (ref. 25) into the active site of the apo-N8 structure 
(2ht5). Specifically, the protein was prepared in the standard manner using Auto-
Dock Tools (version 1.4.5) (ref. 26) and a grid of 70  Å × 60 Å × 60 Å was constructed 
with a spacing of 0.375 points per Å, centred around the active site. The follow-
ing parameters were used in the AutoDocking calculations: ga_pop_size = 250, 
ga_num_evals = 20,000,000, and 250 docking conformations were generated. The 
results were processed using the utilities provided with AutoDock25 and visualized 
using AstexViewer23. AutoDock has been successfully used to predict the binding 
pose and energy of interaction of known inhibitors in the influenza virus sialidase 
active site and confirms that AutoDock is able to reproduce experimentally deter-
mined binding modes with a high degree of accuracy27.
Synthesis of sialic acid derivatives. The sialic acid derivatives 5 and 6 were  
prepared according to Figure 2, using protocols described in the Supplementary  
Information. 1H NMR spectra for the key compounds are provided (Supplementary 
Figs S4–S7).
Viruses. Influenza virus A/Hong Kong/156/97 (H5N1) and influenza virus 
A/California/07/2009 (H1N1 pdm) were kindly provided by Alan Hay (NIMR) and 
by Nancy Cox (Centers for Disease Control), respectively. The influenza viruses 
A/Paris/0497/2007 (H1N1), A/Paris/2590/2009 (H1N1 pdm) and A/Paris/908/97 
(H3N2) were isolated by the National Influenza Center (Northern France) at the 
Institut Pasteur in Paris (France).
Sialidase inhibition assay. The sequence encoding the sialidase was amplified from 
viral RNA by reverse transcription–PCR, and cloned into the pCI vector (Invitro-
gen), using standard procedures. Two independent clones were selected for the neu-
raminidase of each of the three wild-type viruses included in the study. The H274Y, 
N294S and Q136K mutations were each introduced into a plasmidic clone encoding 
the N1 of A/Hong Kong/156/97 or A/Paris/2590/2009, using a QuickChange site- 
directed mutagenesis kit (Stratagene). All constructs were verified by sequencing  
using a Big Dye terminator sequencing kit and an automated sequencer (Perkin 
Elmer). Sialidase inhibition assays were carried out on MES-β-dodecyl-d-maltoside 
cell extracts prepared from 293T cells transiently expressing the viral enzyme, as pre-
viously described13. Sialidase enzymatic activity was measured using the fluorogenic 
substrate 2-α-(4-methylumbelliferyl)-d-N-acetylneuraminic acid (Sigma), according 
to the method of Potier et al.28 Final concentration of the substrate ranged from 5 
to 100 µM. Fluorescence was monitored every 45 s for 20 to 30 min at 37 °C, using 
a Xenius spectrofluorometer (SAFAS) with excitation and emission wavelengths of 
330 and 450 nm, respectively. To measure the inhibitory effect of compounds, cells 
were preincubated for 30 min at 37 °C in the presence of variable concentrations of 
the compounds (0.01–10 nM for zanamivir (1), or 25 nM to 2 µM when tested on the 
Q136K mutant N1; 0.1–100 µM for Neu5Ac2en (4); 6.125–800 µM for 5; 1–400 µM 
for 6), and the substrate was added at a final concentration of 20 µM. Measurements 
are the mean of 2–8 experimentally determined values. The kinetic parameters Vmax, 
Km and Ki were calculated by fitting the data to the appropriate Michaelis Menten 
equations, using the Levenberg–Marquardt algorithm as provided in the commer-
cially available KaleidaGraph software package (Synergy Software).
Cell-based virus inhibition assay. The plaque phenotype of the indicated viruses 
was assayed on MDCK-SIAT cells29 in the presence of serial dilutions of zanamivir 
(1, 0.1 nM to 10 µM), Neu5Ac2en (4, 10 nM to 1 mM), 5 (500 nM to 5 mM) or 
6 (10 nM to 1 mM), using a plaque assay protocol adapted from a published 
procedure30. Cells were stained with crystal violet after 72 h of incubation at 
35 °C. For each inhibitor, the average plaque diameters were plotted against the 
inhibitor concentrations. The EC50 was determined graphically as the concentra-
tion of inhibitor that induced a 50% reduction in the average plaque diameter. 
The A/California/07/2009 H1N1 pandemic strain was used in the plaque reduction 
assay due to its capacity to form larger plaques compared with the corresponding 
A/Paris/2590/2009 H1N1 pandemic strain.
Protein X-ray crystallography. N8 sialidase from A/Duck/Ukraine/1/63 (H3N8) 
was prepared from virus grown in hens’ eggs. Sialidase was released from the virus-
es by bromelain digestion, and further purified, as previously described5. N8 siali-
dase crystals were grown by vapour diffusion in hanging drops consisting of 2 µl of 
reservoir solution (0.1 M imidazole, pH 8.0 and 35% (±)-2-methyl-2,4-pentanediol 
(MPD)) and 2 µl of concentrated protein solution (10 mg ml − 1 in 10 mM Tris–HCl, 
pH 8.0). A crystal of N8 sialidase was soaked in 1 mM 5 or 6 for 60 min. Data were 
collected on an in-house rotating anode (RA Micro7 HFM) and a Saturn944 CCD 
at 100 K and processed with d*Trek31. Standard refinement was carried out with a 
combination of Refmac32 and PHENIX33, together with manual model building with 
O34 or Coot35. Statistical support for the N8–5 and N8–6 structures is presented in 
Supplementary Table S2. Structural data have been deposited with the Protein Data 
Bank with accession codes 3O9J (N8–5) and 3O9K (N8–6). 
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